Evaluation Effectiveness of the Moderna Booster Vaccine on Health
Workers in Indonesia
Inggrya Aliyy Fatma Pradevi and Diana Laila Ramatillah
Faculty Pharmacy, Universitas 17 August 1945 Jakarta, Indonesia
Keywords: Moderna, Booster, Health Workers in Indonesia.
Abstract: This study was conducted to evaluate the effectiveness of the moderna booster vaccine in health workers in
Indonesia. This study used a mixed method and prospective crossectional studies, for all health workers in
Indonesia who have been vaccinated with the third dose of the Moderna vaccine or booster with the
convenience sampling method. The purpose of this study was to find out whether there was a relationship
between the sociodemography of health workers who received the moderna booster vaccine after 6 months
with the incidence of covid-19 and the use of vitamins after vaccination. It was found that the moderna booster
vaccine has an effectiveness of 97.2%. Other factors that influence the side effects and effectiveness of the
vaccine are genders, BMI, and vitamins with a p-value of each variable <0.05. The conclusion is that there
is a relationship between the genders, BMI, and the consumption of vitamins with the effectiveness of the
vaccine.
1 INTRODUCTION
The outbreak that emerged in late 2019 brought a new
disease that is Coronavirus 2019 (COVID-19), the
disease was first discovered in the city of Wuhan, the
capital of Hubei province. In addition to causing
thousands of deaths in China, the virus began to
become a pandemic that spread rapidly to 213
countries, or territories around the world (Ramatillah
and Isnaini 2021). Coronavirus disease 2019
(COVID-19) is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that attacks
the lower respiratory tract (Lee et al. 2020). So far
the World Health Organization has reported more
than 6 million cases of COVID-19 with more than
150 thousand deaths in Indonesia as of June 1 , 2022
(WHO Coronavirus (COVID-19) Dashboard | WHO
Coronavirus (COVID-19) Dashboard With
Vaccination Data n.d.).
Health workers (HW) are those who handle any
work in the health care environment, being at the
forefront of the risk of infection because SARS-
CoV-2 is easily transmitted through the air, direct
contact with contaminated surfaces, exposure in the
workplace, and inadequate use of personal protective
equipment (PPE) (Soebandrio et al. 2021). Some
studies in some countries state that, risk factors
among health workers are lack of PPE, exposure to
infected patients, overwork, poor infection control,
and pre-existing conditions (Adelina and
Dwijayanti 2021).
The Ministry of Health of the Republic of
Indonesia stated that, technically, the Moderna
vaccine has a high efficacy rate and is proven to be
able to significantly suppress the transmission of
COVID-19 in the United States so that the vaccine
A third dose of Moderna is given to health workers
as a booster in order to optimally protect them
(Sekretariat Kabinet Republik Indonesia | Gov’t to
Provide Moderna’s Vaccines for Public, Health
Workers n.d.).
The Moderna COVID-19 vaccine is a vaccine
developed by Moderna and the Vaccine Research
Center at the National Institute of Allergy and
Infectious Diseases (NIAID), within the National
Institutes of Health (NIH) (Baden et al. 2021). This
vaccine is based on messenger RNA (mRNA) which
will later provide instructions to the
host cell to produce the S antigen protein unique
to SARS-CoV-2 so that the body can store immune
information that is generated in immune cell
memory (Moderna mRNA-1273, COVID-19 vaccine
n.d.).
According to research by medxiv on the
Effectiveness of a third dose of BNT162b2 or
156
Pradevi, I. and Ramatillah, D.
Evaluation Effectiveness of the Moderna Booster Vaccine on Health Workers in Indonesia.
DOI: 10.5220/0011977700003582
In Proceedings of the 3rd International Seminar and Call for Paper (ISCP) UTA â
˘
A
´
Z45 Jakarta (ISCP UTA’45 Jakarta 2022), pages 156-164
ISBN: 978-989-758-654-5; ISSN: 2828-853X
Copyright
c
2023 by SCITEPRESS Science and Technology Publications, Lda. Under CC license (CC BY-NC-ND 4.0)
mRNA-1273 vaccine for preventing post-vaccination
COVID-19 infection: an observational study. The
third dose of mRNA-1273 was 46.6% effective in
preventing SARS-CoV-2 infection and 50.0% in
preventing COVID-19 hospitalization. The study
also showed a reduction in post-vaccination infection
in people who received a third dose of the vaccine 6
months after completing the main series of mRNA-
1273 (Sharma, Oda, and Holodniy 2021).
In an observational studyof the third dose of
mRNA was mild (i.e., fatigue, lymphadenopathy,
nausea, and diarrhea) and there was no increase in
which was significant in the EHR reporting of severe
side effects after the third dose compared to after the
second dose (Niesen et al. 2022).
Although data relating to efficacy and side effects
regarding the moderna booster vaccine already exists.
Further clinical research is needed on Effectiveness
Evaluation among Indonesians especially for health
workers by looking at various other aspects such as
sociodemographies that allow there is a link with the
efficacy and side effects of this vaccine.
1.1 Covid-19
SARS-CoV-2 is the novel coronavirus responsible for
the 2019 Coronavirus Pandemic (COVID-19)
disease. Coronavirus disease 2019 (COVID-19) is
caused by the severity of the coronavirus acute
respiratory syndrome (SARS-CoV-2). It has been
declared a new pandemic by the World Health
Organization (WHO) on March 11, 2020. The causes
of COVID-19 are pneumonia and acute respiratory
distress syndrome (ARDS). Other COVID-19
complications may include acute liver, heart, and
kidney injuries, as well as secondary infections and
inflammatory responses. The absence of protective
immunity to the virus and this virus is then able to
escape from the innate immune response. The innate
immune sensing mechanism serves as the first line
of defense antivirals, which is an important aspect of
immunity to viruses (Umar et al. 2021).
SARS-CoV-2, SARS-CoV and MERS-CoV
have a similar structure and phylogenetics, and
consist of four main structural proteins: spike (S),
envelope (E) glycoprotein, nucleocapsid (N),
membrane protein (M), 16 proteins nonstructural, and
5-8 accessory proteins (Moncunill et al. 2022).
1.2 Symptoms of Covid-19
The average incubation period for COVID 19 is 5.2
days, symptoms usually begin with non-specific
syndromes such as fever, dry cough, and malaise.
There are several systems that may be involved such
as the respiratory system (cough, shortness of breath,
sore throat, rhinorrhea, hemoptysis, chest pain),
gastrointestinal (diarrhea, nausea, vomiting),
musculoskeletal system (muscle pain), nervous
system (headache and confusion). More common
signs and symptoms are fever (83% -98%), cough
(76% -82%), and shortness of breath (31-55%). There
are about 15% of cases of fever, cough, and shortness
of breath. No conjunctival injections were reported
in the first series, with some cases under the age of
18. Post-onset symptoms are mild, with the average
time for first hospital admission being 7 days.
However, the disease develops into shortness of
breath on the 8th day, acute respiratory distress
syndrome (ARDS) on the 9th day, and the use of
mechanical ventilation on the 10.5th day occurs in
about 39% of patients (Wu, Chen, and Chan 2020).
However, the clinical condition can quickly
develop into severe pneumonia and eventually,
death, especially in patients who have comorbidities,
such as obesity, type 2 diabetes and cardiovascular
disease (Teotônio et al. 2021).
1.3 Vaccine
The covid-19 vaccine has four types, including
mRNA vaccines were developed by Pfizer-BioNTech
and Moderna. RNA and DNA vaccines are cutting-
edge approaches that use genetic engineering of RNA
or DNA to produce proteins that themselves trigger
an immune response safely. Viral vector vaccines
(adenoviruses) developed by Astra-Zeneca, Johnson
& Johnson, Reithera and Sputnik. Viral vector
vaccines use genetically engineered viruses and do
not cause disease but produce coronavirus proteins to
safely trigger an immune response. An inactivated
viral vaccine was developed by Sinovac. Attenuated
or attenuated viral vaccines use attenuated or
attenuated forms of the virus to obtain an immune
response without causing disease. A protein subunit
vaccine developed by Novavax. Protein-based
vaccines use harmless protein fragments, or protein
shells, that mimic Covid-19 to safely produce an
immune response (Mascellino et al. 2021).
Moderna vaccine also has been one of the
preferred vaccines as it has a higher efficacy which is
94-95% vaccine efficacy that was tested in less than
a year, recommended for 18 y old people and has been
proven to have benefits in preventing SARS-CoV-2
(Article, Araminda, and Ramatillah 2022).
The mRNA-1273 vaccine is administered as a
sterile liquid for injection at a concentration of 0.5 mg
per milliliter. Normal saline is used as a diluent to
Evaluation Effectiveness of the Moderna Booster Vaccine on Health Workers in Indonesia
157
prepare the administered dose (Jackson et al. 2020).
To date, 11.8 billion doses have been distributed and
more than 60% of the population has been vaccinated.
2 MATERIALS AND METHODS
2.1 Design
This study used a mixed method and prospective
crossectional studies, The sampling time is March-
June 2022. The data collection technique carried out
in this study is convenience sampling. Sampling
takes all the items that make up the research inclusion
criteria. The inclusion in this study is all health
workers in Indonesia who received the third dose of
vaccine or booster and are still actively working (not
retired). The exclusion of this study is all health
workers in Indonesia who suffer from cancer, HIV /
AIDS, TB, autoimun.
2.2 Participants
Participants in this study were health workers in
Indonesia that have been conducting a booster dose
of vaccination with the vaccine Moderna. The total of
participants in the study were 323 respondents.
2.3 Instruments
This study used questionnaires distributed through
social media, such as WhatsApp, Twitter, Facebook,
Instagram, and Telegram. The questionnaires
consisting of questions about the identity, efficacy of
the Moderna booster vaccine after the vaccinations,
the short and long term and monitoring the efficacy
of the vaccine for 6 months after being vaccinated.
2.4 Statistical Analysis
The collected results were analyzed using SPSS
application version 25. Fisher, Chi-square, Mann-
Whitney, and Kruskal Wallis tests were then
performed to find the relationship between risk
factors (gender, comorbidities, age, BMI) to the
effectiveness of the vaccine. The value of p <0.05 is
considered significant.
2.5 Ethical Consent
This research has received ethical approval
from the ethics committee of health research at the
University of 17 August 1945 Jakarta, with approval
letter No.37/KEPK-UTA45JKT/EC/EXP/07/2022.
3 RESULTS AND DISCUSSION
In this study, 323 respondents were found who
worked as health workers with an age range of 21-58
years. All respondents have received a covid-19
vaccination booster dose of moderrna which is an
inclusion of this study.
Based on figure 1, it can be seen that the number of
female respondents is higher with a percentage of
75.85% compared to male respondents with a
percentage of 24.15%.
Figure 1: Gender
Respondents who participated in this study were
spread almost throughout Indonesia. The highest
percentage for respondents' domicile was 90.09% for
Java Island, then Sumatra Island with 5.26%,
Kalimantan Island with 3.72%, Sulawesi Island with
presemtasse 0.62%, and Bali island with the lowest
percentage is 0.31%. In this study, researchers were
unable to get respondents with a domicile on Papua
Island.
The percentage of respondents based on domicile
can be seen in figure 2.
the 323 respondents who participated in this
study, the highest percentage for respondents' jobs
was 61.30% for Nurses, then Pharmacists with a
percentage of 10.84%, General Practitioners with a
ISCP UTA’45 Jakarta 2022 - International Seminar and Call for Paper Universitas 17 Agustus 1945 Jakarta
158
percentage 8.98%, Midwives with 7.43%, Pharmacist
Assistants with a percentage of 5.26%, Dentists and
Specialists with 1.86%, Pharmaceutical Technical
Personnel and Dentist Assistants 0.93%,
Radiographers and Radiology Assistants with the
lowest percentage being 0.31%.
The percentage of respondents by occupation can
be seen in figure 3.
Figure 3: Job
In 323 respondents there was 1 respondent with
asthma-borne disease. The percentage of respondents
with comorbidities can be seen in figure 4.
Figure 4: Comorbidities
3.1 Efefectiveness
The effectiveness of the Moderna booster vaccine in
the 1-3rd month is 98.8% and, in the 4th-6th month is
98.5%.
Based on these data, it can be known that the
effectiveness of the Moderna booster vaccine in a
period of 1-6 months is 97.2%. This can be seen in
figure 5.
Figure 5: Effectivenesses of The Moderna Booster Vaccine
3.1.1 Association between Genders with
Vaccine Effectiveness
It can be seen from the data presented in table 1, it is
known that after the vaccine there were 20 female
respondents who had diarrhea, then in 1-3 months
after vaccination there was 1 respondent with female
gender, and 3 respondents with male gender infected
with covid-19. Then 18 female respondents felt a
state of fatigue easily and another 15 female
respondents felt arm pain. Immunotherapy aimed at
stimulating immune responses, e.g. vaccines, develop
a stronger response in women and may experience
greater efficacy than men (Bischof, Wolfe, and Klein
2020)
3.1.2 Association between Jobs with Vaccine
Effectiveness
From the data figure 6, it can be seen that there are 9
out of 11 workers who are recorded as having a fever,
starting from Pharmaceutical Technical Personnel,
Radiographers, Dental Assistants, Specialist Doctors,
Pharmacists and Assistant Pharmacists, Midwives,
Nurses, and the last one is the General Practitioner.
Then for the Radiographer Assistant and Dentist no
symptoms of fever were found.
In the study conducted by Angle, among health
workers at a center in Tel Aviv, Israel who received
the BNT162b2 vaccine had significantly lower
symptomatic and asymptomatic sars-CoV-2 infection
rates for more than 7 days after the second dose.
Results are limited by observational design (Angel et
al. 2021).
323 323
4
5
0
200
400
Infected by Covid-19
after 1-3 month
Infected by Covid-19
after 4-6 month
EFFECTIVENESSES OF THE
MODERNA BOOSTER
VACCINE
Total Infected by Covid-19
Evaluation Effectiveness of the Moderna Booster Vaccine on Health Workers in Indonesia
159
Table 1: Relationship between Genders with Vaccine Effectiveness.
Variable
Female (n=245) Male (n=78)
p-value
Frequency Percentage Frequency Percentage
After the vaccine
Diarrhea 20 8,16% - - 0,049*
1-3 months
Infected with Covid-19
after vaccination
1 0,41% 3 3,85% 0,045*
4-6 months
Easy fatigue 18 7,35% - - 0,006*
Arm pain 15 6,12% - - 0,026*
Figure 6: Relationship Between Job with Vaccine Effectiveness.
0 102030405060
Pharmacist
Pharmacist Assistant
Pharmaceutical Technical Personnel
Radiographer
Midwife
Dentist Assistant
Nurse
General Practitioner
Medical Specialist
CORRELATION BETWEEN JOB AND VACCINE
EFEFCTIVENESS
Fever
ISCP UTA’45 Jakarta 2022 - International Seminar and Call for Paper Universitas 17 Agustus 1945 Jakarta
160
3.1.3 Association between Jobs with Vitamin
Use after Vaccination
Table 2: Relationship between job and vitamins use after vaccination.
Variable
TTK (n=3) Pharmacist (n=35)
Assistant Pharmacist
(n=17)
p-value
Frequency Percentage Frequency Percentage Frequency Percentage
Vitamin C - - 5 14,29% - - 0,016 #
Vitamin C
&Vitamin D3
- - 1 2,86% - - 0,016 #
Vitamin D - - - - - - 0,016 #
Vitamin B12 2 66,67% 2 5,71% 1 5,88% 0,016 #
Table 3: Relationship between job and vitamins use after vaccination.
Variable
Specialist Doctor (n=6)
General Practitioner
(n=29)
Nurse (n=198)
p-value
Frequency Percentage Frequency Percentage Frequency Percentage
Vitamin C - - - - 30 15,15% 0,016 #
Vitamin C
&Vitamin D3
- - 1 3,45% 2 1,01% 0,016 #
Vitamin D - - - - 1 0,51% 0,016 #
Vitamin B12 1 16,67% 5 17,24% 12 6,06% 0,016 #
#Test Chisquare
From the data presented in the table, it can be seen
that a fairly large percentage of respondents who took
vitamin C, vitamin B12, vitamin C & D3, in all jobs
then with the smallest percentage was vitamin D in
Nurses.
In research conducted by Jaehyun showed that
taking vitamin D supplements at doses recommended
by the Endocrine Society can help reduce the risk of
SARS-CoV-2 infection from severe consequences,
including death (Bae et al. n.d.).
The main reason for severe lung pain in COVID-
19 patients is the immune system that does not
function to kill the virus, but instead injures the
patient, causing oxidative stress as well as radicals
free. Vitamin C can reduce oxidative damage and
neutralize these free radicals in the lungs (Sarowar
Uddin et al. n.d.).
In COVID-19 and post-COVID-19 patients,
symptoms such as vitamin B12 deficiency were
found. Studies testing vitamin B12 supplementation
can be used to alleviate some of the symptoms of
various diseases that are also present in COVID-19.
Thus, vitamin B12 can be used in the additional
treatment of mild to severe COVID-19 symptoms,
due to its analgesic function and role in
neuromuscular disorders (Batista et al. n.d.).
In a study conducted by Igor conducted on
hospitalized COVID-19 patients, one high dose of
vitamin D3, when compared to placebo, vitamin D3
did not significantly reduce the duration of
hospitalization. The findings in this study do not
support the use of vitamin D3 for the treatment of
moderate to severe COVID-19 (Murai et al. 2021).
Evaluation Effectiveness of the Moderna Booster Vaccine on Health Workers in Indonesia
161
Table 4: Relationship between job and vitamins use after vaccination.
Variable
Dentist (n=6) Radiology Assistant (n=3)
p-value
Frequency Percentage Frequency Presentation
Vitamin C 1 16,67% - - 0,016 #
Vitamin C
&Vitamin D3
1 16,67% - - 0,016 #
Vitamin D - - - - 0,016 #
Vitamin B12 - - 1 33,33% 0,016 #
Table 5: Relationship between job and vitamins use after vaccination.
Variable
Dental Assistant
(n=3)
Midwife (n=24) Radiographer (n=1)
p-value
Frequency Percentage Frequency Percentage Frequency Percentage
Vitamin C - - 1 4,17% - - 0,016 #
Vitamin C
&Vitamin D3
- - 1 4,17% - - 0,016 #
Vitamin D - - - - - - 0,016 #
Vitamin B12 1 33,33% 4 16,67% 1 100% 0,016 #
3.1.4 Association between BMI with Vaccine
Effectiveness.
Table 6: Presents the relationship between BMI on vaccine effectiveness
Variab
le
Underweight (n=31) Normal (n=265) Overweight (n=24) Obesitas (n=3)
p-
valu
e
Frequen
cy
Percenta
ge
Frequen
cy
Percenta
ge
Frequen
cy
Percenta
ge
Frequen
cy
Presentati
on
Diarrh
ea
- - 17 6,41% 3 12,5% - -
0,04
9 #
Easy
fatigue
1 3,22% 16 6,03% - - 1 3,33%
0,03
2 #
ISCP UTA’45 Jakarta 2022 - International Seminar and Call for Paper Universitas 17 Agustus 1945 Jakarta
162
#Tes Chisquare
It can be seen in the table presented that respondents
with normal weight experience more get tired easily
than diarrhea, respondents with overweight have
more diarrhea, while respondents with underweight
and obesity, they get tired easily.
In the study conducted by Iguacel, respondents
with overweight and obesity experienced fewer side
effects than respondents with normal weight In fact,
in the relationship between side effects COVID-19
vaccines with gender and age are quite significant,
while the status of body weight or BMI, is not
significant (Iguacel et al. 2021).
In the other study by researchers at the University
of Oxford, people with obesity have more risk and the
cause is unknown. It is the same as seasonal flu
infections. Among people with a low BMI the
reduced effectiveness of COVID-19 vaccines may
cause due to frailty or other conditions associated
with low body weight. Further research is needed to
explore the relationship between BMI and immune
responses (Piernas et al. 2022).
4 CONCLUSIONS
In this study, it was found that the effectiveness of the
vaccine was 97.2% and the variables related to the
effectiveness of the vaccine were gender, BMI, and
vitamins. In the sexes, women get greater side effects
than men but have a greater degree of effectiveness,
for the side effects of the moderna booster vaccine in
this study found in female respondents namely;
diarrhea, fatigue, arm pain, and 1 respondent infected
with covid-19, while in men, 3 respondents infected
with covid-19 were found. On the BMI it was found
that the relationship was insignificant. Meanwhile,
vitamins C, B12, and D were found to be able to help
the body in recovery after being infected with covid-
19.
REFERENCES
Adelina, Mutiara, and Fifi Dwijayanti. 2021. “The Infection
of COVID-19 among Health Care Workers in Dharmais
Cancer Hospital.” Indonesian Journal of Cancer 15(1):
1–3. https://www.indonesianjournalofcancer.or.id/e-
journal/index.php/ijoc/article/view/823 (June 1, 2022).
Angel, Yoel et al. 2021. “Association Between Vaccination
With BNT162b2 and Incidence of Symptomatic and
Asymptomatic SARS-CoV-2 Infections Among Health
Care Workers.” JAMA 325(24): 2457–65.
https://jamanetwork.com/.
Article, Original, Gena Nafta Araminda, and Diana Laila
Ramatillah. 2022. “EVALUATION COMPARISON
BETWEEN ASTRAZENECA AND MODERNA
VACCINE’S SIDE EFFECTS AND EFFICACY
AMONG INDONESIA SOCIETY BASED ON
SOCIODEMOGRAPHY.” International Journal of
Applied Pharmaceutics: 37–43.
https://innovareacademics.in/journals/index.php/ijap/ar
ticle/view/44747 (May 30, 2022).
Baden, Lindsey R. et al. 2021. “Efficacy and Safety of the
MRNA-1273 SARS-CoV-2 Vaccine.” The New
England journal of medicine 384(5): 403–16.
https://pubmed.ncbi.nlm.nih.gov/33378609/ (June 1,
2022).
Bae, Jae Hyun et al. “Association of Vitamin D Status with
COVID-19 and Its Severity Vitamin D and COVID-19:
A Narrative Review Mitogen-Activated Protein Kinase
NF-ΚB Nuclear Factor Kappa-Light-Chain-Enhancer
of Activated B Cells OR Odds Ratio RAAS Renin-
Angiotensin-Aldosteron.” Reviews in Endocrine and
Metabolic Disorders 1: 3.
https://doi.org/10.1007/s11154-021-09705-6.
Batista, Kamila S et al. “The Role of Vitamin B 12 in Viral
Infections: A Comprehensive Review of Its
Relationship with the Muscle-Gut-Brain Axis and
Implications for SARS-CoV-2 Infection.”
https://doi.org/10.1093/nutrit/nuab092.
Bischof, Evelyne, Jeannette Wolfe, and Sabra L Klein.
2020. “The Journal of Clinical Investigation Clinical
Trials for COVID-19 Should Include Sex as a
Variable.” 130. https://doi.org/10.1172/JCI139306.
Iguacel, Isabel et al. 2021. “Association between COVID-
19 Vaccine Side Effects and Body Mass Index in
Spain.” https://doi.org/10.3390/vaccines9111321.
Jackson, Lisa A. et al. 2020. “An MRNA Vaccine against
SARS-CoV-2 Preliminary Report L.A.” The new
england journal of medicine Original 383(20).
Lee, Ping Ing et al. 2020. “Are Children Less Susceptible
to COVID-19?” Journal of Microbiology, Immunology
and Infection 53(3): 371–72.
Mascellino, Maria Teresa, Federica Di Timoteo,
Massimiliano De Angelis, and Alessandra Oliva. 2021.
“‘Overview of the Main Anti-SARS-CoV-2 Vaccines:
Mechanism of Action, Efficacy and Safety’ [Response
To Letter].” Infection and Drug Resistance 14: 4501–2.
“Moderna MRNA-1273, COVID-19 Vaccine.”
https://www.who.int/publications/m/item/moderna-
covid-19-vaccine-(mrna-1273) (June 1, 2022).
Moncunill, Gemma et al. 2022. “Determinants of Early
Antibody Responses to COVID-19 MRNA Vaccines in
a Cohort of Exposed and Naïve Healthcare Workers.”
eBioMedicine 75.
Murai, Igor H et al. 2021. “Effect of a Single High Dose of
Vitamin D 3 on Hospital Length of Stay in Patients
With Moderate to Severe COVID-19 A Randomized
Clinical Trial Supplemental Content.”
https://jamanetwork.com/.
Niesen, Michiel J M et al. 2022. “Surveillance of Safety of
3 Doses of COVID-19 MRNA Vaccination Using
Electronic Health Records.”
JAMA Network Open 5(4):
e227038–e227038.
Evaluation Effectiveness of the Moderna Booster Vaccine on Health Workers in Indonesia
163
https://jamanetwork.com/journals/jamanetworkopen/fu
llarticle/2791034 (June 1, 2022).
Piernas, C et al. 2022. “Associations of BMI with COVID-
19 Vaccine Uptake, Vaccine Effectiveness, and Risk of
Severe COVID-19 Outcomes after Vaccination in
England: A Population-Based Cohort Study.” THE
LANCET Diabetes & Endocrinology 10: 571–80.
www.thelancet.com/.
Ramatillah, Diana Laila, and Suri Isnaini. 2021. “Treatment
Profiles and Clinical Outcomes of COVID-19 Patients
at Private Hospital in Jakarta. PLOS ONE 16(4):
e0250147.
https://journals.plos.org/plosone/article?id=10.1371/jo
urnal.pone.0250147 (June 1, 2022).
Sarowar Uddin, Mohammad et al. “The Protective Role of
Vitamin C in the Management of COVID-19: A
Review.” https://doi.org/10.1186/s42506-021-00095-
w.
“Sekretariat Kabinet Republik Indonesia | Gov’t to Provide
Moderna’s Vaccines for Public, Health Workers.”
https://setkab.go.id/en/govt-to-provide-modernas-
vaccines-for-public-health-workers/ (June 1, 2022).
Sharma, Aditya, Gina Oda, and Mark Holodniy. 2021.
“Effectiveness of a Third Dose of BNT162b2 or
MRNA-1273 Vaccine for Preventing Post-Vaccination
COVID-19 Infection: An Observational Study.”
medRxiv: 2021.11.29.21266777.
https://www.medrxiv.org/content/10.1101/2021.11.29.
21266777v1 (June 1, 2022).
Soebandrio, Amin et al. 2021. “COVID-19 Prevalence
among Healthcare Workers in Jakarta and
Neighbouring Areas in Indonesia during Early 2020
Pandemic.” Annals of Medicine 53(1): 1896–1904.
https://www.tandfonline.com/doi/abs/10.1080/078538
90.2021.1975309 (June 1, 2022).
Teotônio, Isabella Márcia Soares Nogueira et al. 2021.
“Clinical and Biochemical Parameters of COVID-19
Patients with Prior or Active Dengue Fever.” Acta
Tropica 214(November 2020): 1–5.
Umar, Abubakar et al. 2021. “Coronavirus Disease 2019 (
COVID-19 ): An Overview of the Immunopathology ,
Serological Diagnosis and Management.” (October
2020): 1–12.
“WHO Coronavirus (COVID-19) Dashboard | WHO
Coronavirus (COVID-19) Dashboard With Vaccination
Data.” https://covid19.who.int/ (June 1, 2022).
Wu, Yi Chi, Ching Sung Chen, and Yu Jiun Chan. 2020.
“The Outbreak of COVID-19: An Overview.” Journal
of the Chinese Medical Association 83(3): 217–20.
https://journals.lww.com/jcma/Fulltext/2020/03000/Th
e_outbreak_of_COVID_19__An_overview.3.aspx
(June 1, 2022).
ISCP UTA’45 Jakarta 2022 - International Seminar and Call for Paper Universitas 17 Agustus 1945 Jakarta
164